We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

111 hedge funds and large institutions have $563M invested in Rhythm Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,454% more call options, than puts

Call options by funds: $4.23M | Put options by funds: $272K

144% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 9

16% more capital invested

Capital invested by funds: $483M → $563M (+$79.3M)

13% more funds holding

Funds holding: 98 → 111 (+13)

0.68% more ownership

Funds ownership: 96.39% → 97.07% (+0.68%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

14% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 37

Holders
111
Holders Change
+13
Holders Change %
+13.27%
% of All Funds
1.75%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
22
Increased
32
Reduced
37
Closed
9
Calls
$4.23M
Puts
$272K
Net Calls
+$3.96M
Net Calls Change
+$3.89M

Top Buyers

Rank Fund Capital Flow
1
Federated Hermes
Federated Hermes
Pennsylvania
+$19.9M
2
RSCM
Rock Springs Capital Management
Maryland
+$5.35M
3
BBA
Baker Bros. Advisors
New York
+$2.3M
4
Citadel Advisors
Citadel Advisors
Florida
+$2.19M
5
Goldman Sachs
Goldman Sachs
New York
+$2.13M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$13.8M
2
State Street
State Street
Massachusetts
-$9.83M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$5.79M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$1.61M
5
Rafferty Asset Management
Rafferty Asset Management
New York
-$1.11M
Name Holding Trade Value Shares
Change 		Change in
Stake
Primecap Management
1
Primecap Management
California
$72.5M +$307K +35,000 +0.6%
Federated Hermes
2
Federated Hermes
Pennsylvania
$58.4M +$19.9M +2,261,778 +81%
NMC
3
NEA Management Company
Maryland
$56.6M – – –
RCM
4
RA Capital Management
Massachusetts
$56.1M – – –
BBA
5
Baker Bros. Advisors
New York
$47.5M +$2.3M +261,823 +7%
Goldman Sachs
6
Goldman Sachs
New York
$38.5M +$2.13M +243,202 +8%
BlackRock
7
BlackRock
New York
$37.8M -$386K -43,956 -1%
Janus Henderson Group
8
Janus Henderson Group
United Kingdom
$34M -$1.61M -182,933 -6%
Vanguard Group
9
Vanguard Group
Pennsylvania
$26M -$584K -66,501 -3%
Franklin Resources
10
Franklin Resources
California
$20.5M +$2.13M +242,582 +16%
RSCM
11
Rock Springs Capital Management
Maryland
$14.3M +$5.35M +609,846 +97%
MAM
12
MPM Asset Management
Massachusetts
$10.5M – – –
State Street
13
State Street
Massachusetts
$9.35M -$9.83M -1,119,907 -58%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$8.54M +$236K +26,861 +4%
Assenagon Asset Management
15
Assenagon Asset Management
Luxembourg
$8.13M +$186K +21,174 +3%
Fidelity Investments
16
Fidelity Investments
Massachusetts
$6.38M +$66.2K +7,547 +1%
Northern Trust
17
Northern Trust
Illinois
$4.8M -$107K -12,184 -3%
Millennium Management
18
Millennium Management
New York
$4.15M +$412K +46,888 +15%
SB
19
Samsara BioCapital
California
$3.98M – – –
Charles Schwab
20
Charles Schwab
California
$3.44M +$80.9K +9,219 +3%
DM
21
Deerfield Management
New York
$3.35M -$13.8M -1,576,462 -84%
Morgan Stanley
22
Morgan Stanley
New York
$2.94M -$113K -12,871 -5%
Citadel Advisors
23
Citadel Advisors
Florida
$2.88M +$2.19M +249,924 New
Deutsche Bank
24
Deutsche Bank
Germany
$2.62M +$1.76M +200,360 +749%
N
25
Nuveen
North Carolina
$2.25M -$21.3K -2,428 -1%
1
2 3 4 5

RYTM Hedge Fund Activity: Q1 2022 in Review

111 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q1 2022, worth a combined $563M — up 16% from $483M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new RYTM positions and 9 closed out — a net gain of 13 holders — while 32 added to existing stakes and 37 trimmed.

The largest buyer was Federated Hermes, adding an estimated $19.9M. The largest seller was Deerfield Management, cutting an estimated $13.8M.

  • 111 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q1 2022, up from 98 in Q4 2021.
  • Funds reported $563M of Rhythm Pharmaceuticals stock for Q1 2022, up 16% quarter-over-quarter.
  • 22 funds opened new Rhythm Pharmaceuticals positions in Q1 2022 and 9 closed out, a net change of +13 holders.
  • The largest Rhythm Pharmaceuticals buyer in Q1 2022 was Federated Hermes, an estimated $19.9M added.
  • The largest Rhythm Pharmaceuticals seller in Q1 2022 was Deerfield Management, an estimated $13.8M sold.

Based on aggregated 13F filings for Q1 2022.